Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Forskningsoutput: TidskriftsbidragÖversiktsartikelVetenskapligPeer review

Sammanfattning

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.
Originalspråkengelska
Artikelnummer1700432
TidskriftAdvanced Healthcare Materials
Volym7
Utgåva1
Sidor (från-till)1700432
Antal sidor23
ISSN2192-2640
DOI
StatusPublicerad - 10 jan 2018
MoE-publikationstypA2 Granska artikel i en vetenskaplig tidskrift

Vetenskapsgrenar

  • 317 Farmaci

Citera det här

@article{eaebf11dcaa249c1a531aee9e22f7be6,
title = "Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines",
abstract = "Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.",
keywords = "317 Pharmacy, cancer therapy, EPR, nanomedicine, tumor microenvironments, tumor targeting, DRUG-DELIVERY SYSTEMS, CELL LUNG-CANCER, METASTATIC BREAST-CANCER, PEGYLATED LIPOSOMAL DOXORUBICIN, ALBUMIN-BOUND PACLITAXEL, PHASE-III TRIAL, MESOPOROUS SILICA NANOPARTICLES, TUMOR-TARGETED NANOMEDICINES, INTERSTITIAL FLUID PRESSURE, HIGH-THROUGHPUT SYNTHESIS",
author = "Vimalkumar Balasubramanian and Zehua Liu and Hirvonen, {Jouni Tapio} and {Almeida Santos}, Helder",
year = "2018",
month = "1",
day = "10",
doi = "10.1002/adhm.201700432",
language = "English",
volume = "7",
pages = "1700432",
journal = "Advanced Healthcare Materials",
issn = "2192-2640",
publisher = "Wiley",
number = "1",

}

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines. / Balasubramanian, Vimalkumar; Liu, Zehua; Hirvonen, Jouni Tapio; Almeida Santos, Helder.

I: Advanced Healthcare Materials, Vol. 7, Nr. 1, 1700432, 10.01.2018, s. 1700432.

Forskningsoutput: TidskriftsbidragÖversiktsartikelVetenskapligPeer review

TY - JOUR

T1 - Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

AU - Balasubramanian, Vimalkumar

AU - Liu, Zehua

AU - Hirvonen, Jouni Tapio

AU - Almeida Santos, Helder

PY - 2018/1/10

Y1 - 2018/1/10

N2 - Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

AB - Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

KW - 317 Pharmacy

KW - cancer therapy

KW - EPR

KW - nanomedicine

KW - tumor microenvironments

KW - tumor targeting

KW - DRUG-DELIVERY SYSTEMS

KW - CELL LUNG-CANCER

KW - METASTATIC BREAST-CANCER

KW - PEGYLATED LIPOSOMAL DOXORUBICIN

KW - ALBUMIN-BOUND PACLITAXEL

KW - PHASE-III TRIAL

KW - MESOPOROUS SILICA NANOPARTICLES

KW - TUMOR-TARGETED NANOMEDICINES

KW - INTERSTITIAL FLUID PRESSURE

KW - HIGH-THROUGHPUT SYNTHESIS

U2 - 10.1002/adhm.201700432

DO - 10.1002/adhm.201700432

M3 - Review Article

VL - 7

SP - 1700432

JO - Advanced Healthcare Materials

JF - Advanced Healthcare Materials

SN - 2192-2640

IS - 1

M1 - 1700432

ER -